Mayo Clinic, Phenomix Awarded First Patent for Weight problems Phenotyping

What You Ought to Know:  

Phenomix Sciences, a precision drugs biotechnology firm that brings data-driven precision drugs to weight problems therapy, introduced it has been awarded the primary patent associated to its weight problems phenotyping expertise. 

– The patent (No. 11,740,247, titled “Strategies and Supplies for Assessing and Treating Weight problems”) covers strategies for treating weight problems by figuring out phenotypes via weight problems analyte signatures and administering interventions, similar to drugs based mostly on that signature. 

What’s weight problems phenotyping?

Phenotyping classifies your sort of weight problems based mostly on particular organic mechanisms. Understanding which of the 4 phenotypes you might have pinpoints what’s driving your weight achieve and limiting your skill to shed extra pounds. Utilizing weight-loss options particular to your phenotype and genetic make-up can double your weight reduction in comparison with standard strategies.

Precision Drugs and Phenotyping to Deal with Weight problems

The expertise underlying the patent was developed by Phenomix’s founders at Mayo Clinic, Andres Acosta, M.D., Ph.D., and Michael Camilleri, M.D., D.Sc. The patent is assigned to Mayo Clinic and completely licensed to Phenomix to develop, manufacture and market weight problems phenotyping checks together with the 2 MyPhenomeTM Checks launched by the corporate earlier within the 12 months. 

The newly granted patent was issued from one in every of 4 households of filed patent functions. The patent functions are directed to numerous features of customized weight problems drugs, together with foundational weight problems phenotyping expertise, analytical and pc applied strategies, phenotype-related way of life interventions and particular predictors of drug response. The claims cowl many kinds of analytes, together with gene variants (SNPs), metabolites, gastrointestinal peptides and hormones; questionnaires, and phenotypes that are linked to particular interventions (e.g., pharmacological brokers).